Faeth Therapeutics, Inc.
FTH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829802
In the last 90 days, Faeth Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 45 institutions reported holding it in 13F filings for Q2 2026, worth $333.8M in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in Faeth Therapeutics, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 25
- +1 vs. Q4 2023
- Shares held
- 2.31M
- −653.4K (−22.1%) vs. Q4 2023
- Total value
- $2.43M
- +$375.5K (+18.3%) vs. Q4 2023
- New holders
- 2
- 4 more added
- Sold out
- 1
- 7 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting FTH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 45 | $333.8M |
| Q1 2026 | 30 | $68.0M |
| Q4 2025 | 10 | $514.8K |
| Q3 2025 | 9 | $466.2K |
| Q2 2025 | 10 | $600.0K |
| Q1 2025 | 20 | $760.2K |
| Q4 2024 | 24 | $1.16M |
| Q3 2024 | 19 | $1.32M |
| Q2 2024 | 24 | $1.31M |
| Q1 2024 | 25 | $2.43M |
| Q4 2023 | 24 | $2.05M |
| Q3 2023 | 23 | $2.38M |
| Q2 2023 | 26 | $3.58M |
| Q1 2023 | 27 | $4.71M |
| Q4 2022 | 28 | $3.93M |
| Q3 2022 | 31 | $4.47M |
| Q2 2022 | 40 | $7.06M |
| Q1 2022 | 43 | $8.21M |
| Q4 2021 | 38 | $19.7M |
| Q3 2021 | 42 | $37.1M |
| Q2 2021 | 34 | $22.7M |
| Q1 2021 | 40 | $45.8M |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Faeth Therapeutics, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Newtyn Management, LLC | 930,230 | $976.7K | 0.19% | −641,793−40.8% | Reduced |
| Vanguard Group Inc | 573,844 | $602.5K | 0.00% | +1930.0% | Added |
| Renaissance Technologies LLC | 211,000 | $222.0K | 0.00% | +67,492+47.0% | Added |
| Geode Capital Management, LLC | 136,318 | $143.2K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 112,900 | $118.5K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 90,763 | $95.3K | 0.00% | −250.0% | Reduced |
| BlackRock Inc. | 33,582 | $35.3K | 0.00% | −1,231−3.5% | Reduced |
| Millennium Management LLC | 32,587 | $34.2K | 0.00% | −5,708−14.9% | Reduced |
| Northern Trust Corp | 26,049 | $27.4K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 25,774 | $27.1K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 23,864 | $25.1K | 0.00% | −1,939−7.5% | Reduced |
| Cresset Asset Management, LLC | 19,671 | $20.7K | 0.00% | +19,671 | New |
| Two Sigma Advisers, LP | 19,000 | $19.9K | 0.00% | 00.0% | Unchanged |
| Leo Wealth, LLC | 14,845 | $15.6K | 0.00% | 00.0% | Unchanged |
| Raymond James & Associates | 14,000 | $14.7K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 12,219 | $12.8K | 0.00% | +12,000+5,479.5% | Added |
| Deuterium Capital Management, LLC | 11,000 | $11.6K | 0.02% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 10,176 | $10.7K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 6,713 | $7.05K | 0.00% | −1,732−20.5% | Reduced |
| Banque Cantonale Vaudoise | 3,900 | $4.00K | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 668 | $701 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 139 | $146 | 0.00% | +139 | New |
| Wells Fargo & Company | 133 | $140 | 0.00% | +2+1.5% | Added |
| Qube Research & Technologies Ltd | 4 | $4 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 53 | $0 | 0.00% | −485−90.1% | Reduced |
| Duquesne Family Office LLCSuperinvestorDuquesne Family Office | 0 | $0 | 0.00% | −100,000−100.0% | Sold out |